Literature DB >> 2271778

Evidence for increased intracellular transport of m-sarcolysine (alkylating moiety) when combined with two amino acid analogs (PTT-119).

F Verlicchi1, S Boschi, G Visani, A Guidi, P Tosi, M Cavo, S Tura.   

Abstract

PTT-119 is an antineoplastic agent in which an alkylating moiety, m-sarcolysine, is linked to two amino acid analogs. Previous studies showed a higher "in vitro" cytotoxicity of PTT-119 when compared to free m-sarcolysine; the mechanisms of this enhanced activity are not completely understood. In this study we incubated peripheral blood cells from 8 chronic lymphocytic leukemia patients with both m-sarcolysine and equimolar concentrations of PTT-119, measuring the intracellular concentration of the alkylating moiety. We observed a significantly higher intracellular concentration of m-sarcolysine in cells incubated with the peptide-bound drug than with the free drug (58.3 +/- 39.6 versus 4.4 +/- 1.9 ng/10(6) cells; P = 0.013). This observation could explain the higher cytotoxic activity of PTT-119 and the lack of cross-resistance with melphalan.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2271778     DOI: 10.1007/bf01732884

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  13 in total

1.  Phase II cooperative study with a new alkylating drug, PTT-119, in the treatment of non-Hodgkin's lymphomas.

Authors:  F Gherlinzoni; P Mazza; P L Zinzani; S Tura; F Lanza; G Castoldi; G Bellesi; P L Rossi Ferrini; L Mangoni; V Rizzoli
Journal:  Blut       Date:  1990-03

2.  Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma.

Authors:  G Visani; R M Lemoli; P Tosi; F Verlicchi; B Gamberi; A R Cenacchi; R Colombini; M Fogli; D Russo; E Zuffa
Journal:  Blut       Date:  1990-05

3.  Differential DNA cross-linking and cytotoxicity in PHA-stimulated human lymphocytes exposed to melphalan, m-L-sarcolysin and peptichemio.

Authors:  R Lewensohn; J Hansson; U Ringborg; H Ehrsson
Journal:  Eur J Cancer Clin Oncol       Date:  1987-06

4.  Evidence for active transport of melphalan by two amino acid carriers in L5178Y lymphoblasts in vitro.

Authors:  A Begleiter; H Y Lam; J Grover; E Froese; G J Goldenberg
Journal:  Cancer Res       Date:  1979-02       Impact factor: 12.701

5.  Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas.

Authors:  S Tura; P Mazza; F Gherlinzoni; P L Zinzani; G Poletti; G Visani; R M Lemoli; M Cavo; P Galieni; C Tassi
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  DNA-damage in human cells treated with the closely related alkylating agents peptichemio, m-L-sarcolysin and melphalan.

Authors:  U Ringborg; B Lambert; R Lewensohn; I Turesson
Journal:  Eur J Cancer Clin Oncol       Date:  1981-09

7.  Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro.

Authors:  G J Goldenberg; H Y Lam; A Begleiter
Journal:  J Biol Chem       Date:  1979-02-25       Impact factor: 5.157

8.  Synthesis, acute toxicity and chemotherapeutic anti-cancer activities of a new tripeptidic mustard.

Authors:  A De Barbieri; L Dall'Asta; A Comini; V Springolo; P Mosconi; G Coppi
Journal:  Farmaco Sci       Date:  1983-04

9.  Increased cancericidal activity of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. I. In vitro cytotoxicity.

Authors:  M J Yagi; J G Bekesi; M D Daniel; J F Holland; A De Barbieri
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

10.  PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met ethoxy HCl, a new chemotherapeutic agent active against drug-resistant tumor cell lines.

Authors:  M J Yagi; S E Chin; K J Scanlon; J F Holland; J G Bekesi
Journal:  Biochem Pharmacol       Date:  1985-07-01       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.